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ABSTRACT
The development of nonmyeloablative (NM) hematopoietic cell transplantation (HCT) has extended the
potential curative treatment option of allografting to patients in whom it was previously contraindicated
because of advanced age or comorbidity. Acute and chronic graft versus host disease (GVHD) and its
consequent nonrelapse mortality (NRM), remains the major limitation of NM HCT. In this report, we
analyzed the outcome of 67 patients (median age, 45 years) with hematologic diseases receiving NM condi-
tioning with fludarabine 90 mg/m2 and total body irradiation (TBI) 200-cGy, followed by filgrastim-mobilized
peripheral blood stem cell transplant from HLA identical (n  61), 5/6 antigen-matched related (n  1), 6/6
antigen-matched unrelated (n  3), and 5/6 antigen-matched unrelated (n  2) donors. The first cohort of 21
patients were given cyclosporine (CSP) and mycophenolate mofetil (MMF) as postgrafting immunosuppres-
sion, whereas the subsequent cohort was given additional methotrexate (MTX) and extended duration of
CSP/MMF prophylaxis in an attempt to reduce graft-versus-host disease (GVHD). Sixty-four (95%) patients
engrafted and 3 (5%) had secondary graft failure. Myelosuppression was moderate with neutrophil counts not
declining below 500/L in approximately 25% of patients, and with more than half of the patients not requiring
any blood or platelet transfusion. The 2-year cumulative interval (CI) of grade II-IV, grade III-IV acute GVHD
and chronic GVHD were 49%, 30%, and 34%, respectively. The 2-year probability of NRM, overall (OS), and
progression-free (PFS) survival were 27%, 43%, and 28%, respectively. GVHD-related death accounted for
85% of NRM. Compared with patients receiving CSP/MMF, patients receiving extended duration of CSP/
MMF with additional MTX in postgrafting immunosuppression had a significantly lower risk of grade III-IV
acute GVHD (CI 20% versus 52%; P .009) and NRM (CI at 2 years: 11% versus 62%; P< .001), without any
significant adverse impact on the risk of relapse (CI at 2 years: 59% versus 33%; P  .174) Subgroup analysis
of a cohort of patients given MTX/CSP/MMF showed that patients with “standard risk” diseases (n  21) had
a 3-year OS and PFS of 85% and 65%, respectively. This compares favorably to the 41% (P  .02) and 23%
(P  .03) OS and PFS, respectively, in patients with “high-risk” diseases (n  25). In conclusion, the addition
of MTX onto the current postgrafting immunosuppression regimen with extended CSP/MMF prophylaxis
duration provides more effective protection against severe GVHD, and is associated with more favorable
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GVHD Prophylaxis in Nonmyeloablative Transplant 791outcome in patients receiving NM fludarabine/TBI conditioning than in patients receiving fludarabine/TBI
conditioning with CSP and MMF without MTX.
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Allogeneic hematopoietic cell transplantation
HCT) after myeloablative conditioning regimens has
een an effective treatment for many patients with
ematologic malignancies or inherited blood disor-
ers. Unfortunately, such regimens have been associ-
ted with signiﬁcant toxicities, limiting their use to
therwise healthy, relatively young patients. To ex-
end allogeneic HCT to older patients and those with
omorbid conditions, reduced-intensity or truly non-
yeloablative (NM) conditioning regimens lacking
uch toxicities [1-4] have been developed. These reg-
mens have relied more on graft-versus-tumor effects
han on chemoradiation therapy to facilitate engraft-
ent and eradicate malignant cells. Although NM
CT has been associated with reduced regimen-re-
ated toxicities and has been curative for a number of
atients with hematologic malignancies, challenges
ave remained with regard to graft-versus-host disease
GVHD), infections, and disease progression. Acute
VHD (aGVHD) (grade II or higher), which devel-
ped in 20% to 65% of patients in single or multi-
enter clinical trials [4-6], remains a major limitation
o success of NM HCT. Furthermore, recent analysis
uggests that aGVHD, particularly early-onset
VHD, is associated with increased transplant-re-
ated mortality (TRM) [7], but not with improved
isease control, for which chronic GVHD (cGVHD)
ppears more important [8].
In an attempt to reduce GVHD-related death,
arious approaches have been employed. In vivo T cell
epletion, such as incorporating alemtuzumab into
he conditioning regimen, has been shown to reduce
he incidence of GVHD [9-13]. However, this type of
ntervention, although reducing GVHD, may have an
dverse impact on disease response. This is because of
he inverse relationship between GVHD and relapse
f malignancies [14-16] and the fact that NM HCTs
xhibit their antitumor activity by relying on a graft-
ersus-malignancy effect [2,3,17-19]. In fact, several
onrandomized studies have demonstrated that such
trategies have resulted in a reduction in risk for
VHD without any survival beneﬁt [20-23]. Clearly,
ptimizing GVHD control without reducing graft-
ersus-malignancy effects after NM conditioning re-
ains a critical research objective.
Different immunosuppressive drug combinationsave also been evaluated in efforts to decrease thencidence and severity of GVHD [24-35]. However,
he most effective combination and the optimal dura-
ion of immunosuppressive therapy to protect against
VHD have not been deﬁned.
Here we report the results of a prospective pilot
rial evaluating the feasibility and efﬁcacy of allogeneic
CT after 2 Gy total body irradiation (TBI) and
udarabine NM conditioning developed in Seattle
3,4,36], followed by postgrafting immunosuppression
ith mycophenolate mofetil (MMF) and cyclosporine
CSP) in 67 patients with various hematologic dis-
ases. In this study, a second patient cohort was ac-
rued based on the modiﬁcation of postgrafting im-
unosuppression, which was made following the
bservation of a considerably high incidence of severe
VHD in the ﬁrst patient cohort. These 2 sequential
atient cohorts, which differed only by GVHD pro-
hylaxis regimen, allow us to compare the efﬁcacy of
different immunosuppressive combination regimens
n transplantation outcome.
ATIENTS, MATERIALS, AND METHODS
atient Eligibility and Donors
Included in the study were results from 67 con-
ecutive patients with hematologic diseases treated at
tertiary centers in Singapore between November
999 and October 2005. Treatment protocols were
pproved by the ethics committee or institution re-
iew board at each institution. Informed consent was
btained from all patients and donors before treat-
ent initiation. Patients with lymphoma, aplastic ane-
ia, acute leukemia, myelodysplasia, multiple my-
loma, chronic myelogenous leukemia (CML), and
hronic lymphocytic leukemia, between ages 45 and
0 years were considered eligible. Patients were also
ligible if they were younger than 45, but deemed
oor candidates for conventional conditioning because
f (1) medical comorbidities (eg, renal dysfunction,
iver cirrhosis, existing fungal infections); (2) extensive
rior therapy resulting in poor performance status; or
3) failed prior autologous transplantation. Exclu-
ion criteria were cardiac ejection fraction 35%;
iffusion capacity of carbon monoxide 35% pre-
icted; bilirubin 2 times and/or transaminase 4
imes the upper limit of normal, and Karnofsky
erformance score 50.HLA typing of patients and their donors were
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L.-P. Koh et al.792erformed using the standard serologic techniques or
ow/intermediate resolution DNA techniques for
LA-A and -B antigens, and serologic level or high-
esolution DNA techniques for HLA-DR antigens.
or unrelated donors, high-resolution DNA tech-
iques were performed for all HLA class I and II
ntigens. Donors included 61 HLA-identical siblings,
sibling with 1 class I antigen mismatch, 3 matched
nrelated donors, and 2 unrelated with 1 class I anti-
en mismatch. Twenty-four cytomegalovirus (CMV)-
eronegative patients had 17 seronegative and 7 sero-
ositive donors. Among 43 seropositive patients, 31
ad seropositive donors and 12 had seronegative do-
ors.
reatment and Evaluations
Patients were treated with 3 doses of ﬂudarabine,
0 mg/m2 per day, from days 4 to 2 and a single
raction of 2-Gy TBI delivered at 0.07 Gy/min from
inear accelerators on day 0, followed by donor hema-
able 1. Continued
All
Non-MTX-
Containing
(CSP/MMF)
MTX-
Containing
(CSP/MMF/
MTX)
PNo. (%) No. (%) No. (%)
ell dose, 106/kg
recipient
CD34 cells
Median 6.04 5.53 6.31 .74
Range 1.12-22.89 1.12-21.63 1.68-22.89
CD3 cells .29
Median 2.97 3.23 2.85
Range 1.34-5.40 1.38-5.09 1.34-5.40
DS indicates myelodysplastic syndromes; AML, acute myeloge-
nous leukemia; CML, chronic myelogenous leukemia; ALL,
acute lymphoblastic leukemia; CLL, chronic lymphocytic leu-
kemia; CR, complete remission; PR, partial remission; MTX,
methotrexate; HCT, hematopoietic cell transplant; MMF, my-
cophenolate mofetil; CSP, cyclosporine.
Standard risk was deﬁned as AML/ALL/myeloma/lymphoma in
ﬁrst remission, chronic myelogenous leukemia in the ﬁrst
chronic phase, myelodysplastic syndrome-refractory anemia,
aplastic anemia. All other diagnoses were classiﬁed as high risk.
*High risk CMV indicates patient CMV, low/intermediate risk,
patient and the donor or 48.
This includes all leukemia, myeloma, lymphoma, or MDS in ﬁrst
complete remission following chemotherapy.
†This includes the patients who failed induction, relapsed diseases,
failed to achieve complete remission with chemotherapy, and
CML beyond ﬁrst chronic phase.
This include patients with CML in the ﬁrst chronic phase, aplastic
anemia, MDS that proceeded to transplant without prior che-
motherapy.
Two sided P-values comparing “MTX-containing group” and
“non-MTX-containing group” from Mann-Whitney U test for
recipient age, donor age, number of prior regimens, CD34
cells, and CD3 cell count; 2 or Fischer’s exact test for all other
factors.able 1. Characteristics of 67 Patients with Nonmyeloablative
ematopoietic Cell Transplantation
All
Non-MTX-
Containing
(CSP/MMF)
MTX-
Containing
(CSP/MMF/
MTX)
PNo. (%) No. (%) No. (%)
atients studied 67 21 46
ecipient sex .8
Male 34 (51) 10 (48) 24 (52)
Female 33 (49) 11 (52) 22 (48)
ecipient age, years .3
Median 45.5 48 43
Range 16-63 19-59 16-63
onor sex .4
Male 42 (63) 15 (71) 27 (59)
Female 25 (37) 6 (29) 19 (41)
onor age, years .33
Median 44 45 44
Range 20-62 23-62 20-59
emale donor/male
recipient 17 (25) 5 (24) 12 (26) .7
ge group .1
<30 y 11(16) 3 (14) 8 (17)
31-40 y 9 (13) 0 (0) 9 (20)
41-50 y 28 (42) 11 (53) 17 (37)
51-60 y 16 (24) 7 (33) 9 (20)
>60 y 3 (5) 0 (0) 3 (6)
iagnosis .06
AML 15 (22) 8 (38) 7 (15)
MDS/2° Leukemia 16 (24) 0 (0) 16 (35)
CML 14 (21) 7 (33) 7 (15)
ALL 1 (1.5) 1 (5) 0 (0)
Myeloma 10 (15) 3 (14) 7 (15)
Aplastic anemia 8 (12) 2 (10) 6 (13)
CLL 1 (1.5) 0 (0) 1 (2)
Hodgkin 1 (1.5) 0 (0) 1 (2)
Myelofibrosis 1 (1.5) 0 (0) 1 (2)
isease status .24
CR1† 8 (12) 4 (19) 4 (9)
PR/relapse/
refractory†† 31 (46) 11 (52) 20 (43)
Untreated‡ 28 (42) 6 (29) 22 (48)
isease risk* .3
Standard risk 34 (51) 13 (62) 21(46)
High risk 33 (50) 8 (38) 25 (54)
rior autologous
HCT 11 (16) 4 (19) 7 (15) .5
MV risk group** .01
High risk 43 (64) 18 (86) 25 (54)
Low/intermediate
risk 24 (36) 3 (14) 21 (46)
umber of prior
regimens .6
Median 1 1 1
Range 0-4 0-3 0-4
onor .4
ibling
HLA identical 61 (91) 19 (90) 42 (92)
1 antigen HLA
mismatched 1 (1) 0 (0) 1 (2)
nrelated
HLA identical 3 (5) 2 (10) 1 (2)
1 antigen HLAopoietic cell infusions. On the day of transplantation,
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GVHD Prophylaxis in Nonmyeloablative Transplant 793atients received unmanipulated allogeneic peripheral
lood stem cell grafts mobilized with granulocyte col-
ny-stimulating factor (G-CST) containing a median
f 6.04 (range: 1.12-22.89) 106 CD34 cells/kg, and
median of 2.97 (range: 1.34-5.40)  108 CD3
ells/kg from their HLA-matched related donor (n 
2) or unrelated donor (n 5). In the initial protocols,
SP was administered orally at 6.25 mg/kg twice
aily. CSP levels were targeted to the individual in-
titution’s therapeutic range until day 35 and then
apered through day 56 for related recipients or
ntil day 100 for unrelated recipients. MMF was
iven orally at 15 mg/kg twice a day or 10 mg/kg
hrice a day starting from day 0 to day 27 for related
ecipients or until day 40 at full dose and then tapered
hrough day 96 for unrelated recipients. In an at-
empt to decrease the observed incidence of GVHD,
odiﬁcation of postgrafting immunosuppression was
ade after July 2001 by adding standard course of
ethotrexate (MTX) at 15 mg/m2 day 1, 10 mg/m2
n day3, day6, and day11. In addition, because
f evolving treatment protocols, the duration of MMF
nd CSP was extended in the following manner: (1)
SP was given until day 80, and tapering was initiated
n the absence of GVHD, until day 180; (2) MMF was
iven full dose until day 54, followed by a taper over 4
eeks. Accordingly, the ﬁrst 21 patients received
MF and CSP (non-MTX-containing regimen) and
he following 46 patients received extended MMF and
SP in addition to MTX (MTX-containing regimen)
s postgrafting immunosuppression. Patients’ charac-
eristics were compared between those that were given
he CSP/MMF 2-drug regimen versus those who were
iven the 3-drug regimen using MTX/CSP/MMF, as
epicted in Table 1.
Antibacterial, antifungal, and antiviral prophylaxes
ere performed according to institutional protocols.
hese included trimethoprhim/sulfamethoxazole for
neumocystis carinii prophylaxis, acyclovir for herpes
implex virus prophylaxis, and itraconazole or ﬂucon-
zole for fungal prophylaxis. Patients were screened
or CMV infection by PCR detection of viral DNA or
y the viral pp65 antigenemia assay. Preemptive in-
ravenous ganciclovir or foscarnet was given according
o institutional guidelines. All blood products were
rradiated (2500 cGy) and ﬁltered before they were
nfused. Immunoglobulin was administered to all pa-
ients in a dose of 250 mg/kg weekly from day 7 to
ay 54.
Patients with neutropenic fever were treated with
road-spectrum antibiotics according to institutional
rotocols. Bone marrow aspiration was performed
outinely 4 weeks after infusion and then 3 and 12
onths later; aspirates were sent for morphologic
valuation, ﬂow cytometry, cytogenetics, and chimer-
sm evaluation. The levels of donor chimerism at
ranulocytes and mononuclear cells from peripheral slood or marrow were assessed at days 14, 28, 56, 84,
80, and 360 after HCT using FISH to detect X and
chromosomes for recipients of grafts from sex-
ismatched donors, and PCR-based ampliﬁcation of
ariable numbers of tandem repeat sequences as pre-
iously described [37].
The primary endpoints of the study were to assess
ngraftment, regimen-related toxicity, nonrelapse
ortality (NRM) and incidence of GVHD. The sec-
ndary endpoints included response rate, overall sur-
ival and progression-free survival (PFS). aGVHD
nd cGVHD were assessed according to the standard
riteria [38,39]. With previous reports from Seattle
hat the median onset of GVHD was substantially
elayed after NM versus myeloablative conditioning,
linical ﬁndings consistent with syndrome of aGVHD
hat appear after day 100 were also labeled as aGVHD
late-onset aGVHD) [46]. Toxicities were determined
sing the National Cancer Institute Common Toxic-
ty Criteria, version 2 [40].
tatistical Analysis
In the evaluation of engraftment, patients who
ied before day 22 without engraftment were con-
idered not evaluable and censored at time of death.
atients who died after day 22 without engraftment
ere considered as graft failures and censored at death
r at day 42, whichever came ﬁrst.
Data were analyzed according to previously pub-
ished guidelines for assessment of outcomes after
ransplantation [41,42]. Time-to-event outcomes with
ompeting risks (ie, NRM, relapse incidence, and
VHD) were estimated using cumulative-incidence
urves by implementing the SAS macro as described
y Tai et al. [43]. Time to NRM was deﬁned from the
ate of transplantation until death from causes other
han relapse, with relapse deﬁned as a competitive
isk. Similarly, NRM was deﬁned as a competitive risk
n analysis of relapse incidence, and death without
VHD as a competitive risk in GVHD analysis.
Progression free survival was deﬁned only for pa-
ients who achieved complete remission (CR) and was
easured from the date of CR until relapse or death,
egardless of cause. Current PFS (CPFS) was calcu-
ated on the basis of disease status at last follow-up
41,44]. Patients who relapsed but responded to ap-
ropriate “salvage” therapy (second transplant, che-
otherapy, or donor lymphocyte infusion) without
ubsequent progression at the time of analysis were
ensored at the last follow-up date in the analysis of
PFS. The time to event was deﬁned as time from
rst transplant to time of hematologic relapse, death,
r last contact in remission. Probabilities of overall
urvival (OS), PFS, and CPFS were calculated by the
ethod of Kaplan and Meier [45] and differences in
urvival distributions between groups were compared
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L.-P. Koh et al.794sing the log-rank statistic [47]. In the analysis of OS
nd PFS, adjustment for prognostic factors was made
sing Cox regression, with aGVHD and cGVHD
egarded as time-dependent covariates. All statistical
nalyses were performed using the SPSS version 13.0.
ESULTS
atient Characteristics, Engraftment,
nd Donor Chimerism
Data were analyzed as of March 31, 2006. The
edian follow-up for surviving patients was 25
onths (range: 6-72 months). Patient characteristics
re summarized in Table 1. The median patient age
as 45.5 years (range: 16-63 years), whereas the me-
ian donor age was 44 years (range: 20-62 years).
wenty-eight patients with age 45 years had NM
ransplant with the following primary indications: (1)
ailed prior autologous transplantation (N  11); (2)
edical comorbidities or organ dysfunction (N  12);
nd (3) patients’ decision because of the concern about
egimen-related toxicity of myeloablative condition-
ng (N  5). The median interval between diagnosis
o HCT was 6 months (range: 1-60 months). Pre-
ransplant treatment was heterogenous with a median
f 1 (range: 0-4) prior chemotherapy regimen. At the
ime of HCT, 21 patients (30%) had chemotherapy-
efractory disease. Eleven patients (16.4%) had re-
apsed from prior autologous HCT. Patients were
lassiﬁed as being at standard or high risk for disease
rogression after HCT as described in Table 1.
Among the entire cohort of 67 patients, 2 patients
ith refractory leukemia died of pneumonia before
ay 14, leaving 65 patients evaluable for engraftment.
mong these 65 patients, all but 1 engrafted. This
atient with CML has prior secondary graft failure
rom previous allograft using a different reduced in-
ensity conditioning regimen. She was treated with
matinib and was later enrolled into a phase II clinical
rial using dasatinib and is currently in partial response
years after HCT.
Neutrophil counts 0.5  109/L was achieved
fter a median of 17 days (range: 9-29 days), and
latelet counts more than 20  109/L was achieved
fter a median of 14 days (range: 6-21 days). The
edian number of days in which absolute neutrophil
ount (ANC) was 0.5  109/L was 6 days (range:
-25 days) and 17 (26%) patients maintained ANC
0.5  109/L after HCT. Thirty-nine patients (60%)
aintained platelet count 20  109/L after HCT.
hirty-six (54%) patients did not require any transfu-
ions, 41 (61%) did not require platelet transfusions,
nd 38 (57%) did not require any red blood cell
ransfusions.
The median percentage of donor chimerism per-
ormed at days 14, 28, 54, 84, 180, and 365 were 50%, r5%, 95%, 95%, 100%, and 100%, respectively. At 6
onths, 28 (42%) patients with diseases in complete
emission had 95% donor chimerism. At 1 year, 19
28%) patients were in remission and had complete
onor cell engraftment.
Three matched-related recipients with myeloﬁ-
rosis (n  1), CML (n  2), after their initial en-
raftment and attainment of mixed chimerism ranging
etween 75% and 95%, rejected their graft on day 83,
ay 130, and day 180, respectively. Graft rejection
receded disease progression or relapse in all these
atients, and despite withdrawal of immunosuppres-
ant followed by donor lymphocyte infusion (DLI),
here was no response. One patient with CML was
iven imatinib and achieved complete remission. An-
ther patient committed suicide because of depression
n day 130 of HCT. A patient with myeloﬁbrosis had
isease recurrence with recurrent splenomegaly and
arrow ﬁbrosis after initial complete remission (CR).
he is now in stable disease at 2 years after HCT with
o therapy.
VHD
With 2 early toxic deaths and 1 primary graft
ailure, only 64 patients were evaluable for aGVHD.
GVHD of grade II-IV developed in 52% of these 64
valuable patients: grade II in 13 (20%), grade III in
9 (30%), and grade IV in 1 (2%). The median day of
nset was 30 days (range: 11-182 days). Skin, liver, and
ut were affected in 15, 18, and 19 patients, respec-
ively. In most cases, aGVHD was treated with corti-
osteroids alone. In 4 patients, OKT3, rapamycin, or
aclizumab were used because of inadequate response
o corticosteroids. The 2-year cumulative incidence of
rade II-IV and grade III-IV aGVHD were 49%
95% conﬁdence interval [CI] 37%-62%) and 30%
95% CI 19%-41%), respectively (Figure 1A). Com-
eting risk analysis demonstrated the use of MTX-
ontaining regimen with extended duration of CSP
nd MMF as the only variable that was associated with
lower risk of developing grade III-IV aGVHD (20%
ersus 52%, difference in cumulative incidence, 32%;
5% CI 8%-58%; P  .009) (Figure 1B; Table 2).
here was no signiﬁcant difference in the incidence of
rade II-IV GVHD between the 2 immunosuppres-
ive regimens (P  .512).
There was no signiﬁcant difference in the time to
nset of aGVHD between the 2 immunosuppressive
egimens. Acute grade II-IV GVHD occurred at the
edian time of 32 days (range: 17-182 days) and 26
ays (range: 11-101 days), respectively, for patients
eceiving non-MTX-containing and MTX-containing
mmunosuppressive regimens (P  .49). Acute grade
II-IV GVHD occurred at the median time of 35 days
range: 17-182 days) and 32 days (range: 11-86 days),
espectively, for patients receiving non-MTX- con-
Figure 1. A, Cumulative incidence of aGVHD and cGVHD of 67 patients undergoing nonmyeloablative allogeneic transplantation. B, Grade III-IV GVHD. C, Chronic GVHD of 67 patients
undergoing nonmyeloablative allogeneic transplantation stratiﬁed by postgrafting immunosuppression.
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L.-P. Koh et al.796aining and MTX-containing immunosuppressive
egimens (P  .58).
Given that patients on MTX-containing GVHD
rophylaxis regimen were also on the extended CSP/
MF protocol, we asked the question of whether this
ould have any impact on the incidence and severity of
GVHD. However, with at least half of patients in the
on-MTX-containing arm remaining on CSP/MMF
onger than speciﬁed by protocols because of occur-
ence of aGVHD, the impact of extended CSP/MMF
n the incidence or severity of aGVHD could not be
dequately addressed in the current study.
Fifty-three patients surviving beyond 100 days
ere evaluable for cGVHD. Overall, cGVHD devel-
ped in 19 patients at a median time of 123 days
range: 102-396 days) after transplantation. The
-year cumulative incidence of cGVHD was 34 %
95% CI 21%-46%) (Figure 1A). Fourteen had lim-
ted disease and 5 had extensive disease. Fourteen
21%) patients died without relapse of their disease
rom complications arising from either aGVHD or
GVHD. The 2-year cumulative incidence of cGVHD
as not statistically different between patients receiv-
ng the 2 postgrafting immunosuppression regimens,
lthough there was a trend toward a higher incidence
f cGVHD in patients given MTX-containing regi-
en (39% versus 18%; difference in cumulative inci-
ence, 21%; 95% CI 9%-51%; P  .177) (Figure 1C;
able 2).
oxicity and Nonrelapse Mortality (NRM)
Mild to moderate nausea caused by CSP/MMF
as common. No patient experienced new onset of
lopecia or veno-occlusive disease. Thirteen-patients
able 2. Two-Year Outcome Probabilities of all Patients and
tratiﬁed by Postgrafting Immunosuppression
Outcomes
Postgrafting Immunosuppression
P
All
Patients
(N  67)
CSA/MMF
(N  21)
CSA/MMF/
MTX
(N  46)
% % %
onrelapse mortality* 27 62 11 <.001
elapse* 50 33 59 .174
verall survival† 43 5 60 <.001
rogression-free
survival† 28 0 42 <.001
rade III-IV acute
GVHD** 30 52 20 .009
hronic GVHD* 34 18 39 .177
VHD indicates graft-versus-host disease.
Cumulative incidence.
*Six-month cumulative incidence.
Kaplan-Meyer estimate.
P values are based on comparisons of outcome between the 2 arms
of postgrafting immunosuppression.32%) did not have any regimen-related toxicity or
Infection during the ﬁrst 100 days of transplant. In
ontrast, grade III-IV regimen-related toxicities were
een in 32 (47%) patients, causing deaths in 15 cases.
he most frequent grade III and IV toxicities are
hown in Table 3.
Within the ﬁrst 30 days, an increase of serum
reatinine and bilirubin of 1.5 times upper normal
imit was documented in 15 (22%) and 24 (36%)
atients, respectively. The majority of these cases
ere transient and reversible, and were ascribed to
SP, concomitant medications, or infections.
Eighteen (27%) died from nonrelapse causes, in-
luding GVHD (n  14), pneumonia (n  3), and
ulmonary hemorrhage (n  1). The cumulative in-
idences of NRMwere 18% (95% CI 9%-27%) at day
00 and 27% (95% CI 16%-38%) at 1 year, respec-
ively. Competing risk analysis identiﬁed the use of
TX-containing GVHD prophylaxis regimen as the
nly pretransplantation variable that was associated
ith lower risk of NRM (11% versus 62%; difference
n cumulative incidence, 51%; 95% CI 26%-76%,
 .001) (Figure 2A; Table 2).
Overall, infection-related death occurred in 24
36%) patients, with 11 (16%) of these occurring
ithin the ﬁrst 100 days of transplantation. Twenty-
ne (31%) of these cases were associated with
GVHD (N  12) or underlying persistent residual
iseases (N  9). Thirteen (19%) patients developed
neumonia caused by fungi (n  8), bacteria (n  3),
nd of unknown etiologies (n  2), leading to death in
2 cases. Nineteen (28%) patients developed neutro-
enic fever before engraftment. Bacteremia was doc-
mented in 5 (8%) patients, causing death in all the 5
ases. Proved or probable invasive aspergillosis oc-
urred in 7 patients with grade III-IV GVHD receiv-
ng steroid prednisolone 1 mg/kg/day and 1 patient
ith refractory acute myelogenous leukemia (AML).
nly 2 of these were successfully treated. The remain-
ng 6 patients died either of refractory disease (n  1)
r of GVHD (n  5).
Eighteen (42%) of the 43 patients at high risk of
nfection with CMV (ie, seropositive recipients) and
1 (46%) of the 24 low/intermediate-risk patients (se-
onegative recipients and seropositive or seronegative
onors) developed CMV antigenemia [47]. All pa-
ients were treated successfully with either ganciclovir
r foscarnet; none developed CMV disease. Although
ore patients in the group receiving CSP/MMF were
t higher risk of CMV infections, no difference in the
able 3. Incidence of Grade III and IV Toxicities in 67 Patients
eceiving Nonmyeloablative Hematopoietic Cell Transplant
Grade Renal Hepatic Pulmonary GI Mucositis Hemorrhage
II 4 8 2 5 0 0
V 0 0 13 0 1 2
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GVHD Prophylaxis in Nonmyeloablative Transplant 797ncidence of CMV antigenemia and disease in the 2
roups was noted.
The anticipated complications associated with the
se of MTX were compared between the 2 cohorts of
atients. The addition of MTX in the postgrafting
mmunosuppression was associated with a trend to-
ard higher incidence of mucositis (9% versus 0%),
onger duration of neutropenia (median duration 9.5
ays versus 1 day) and thrombocytopenia (median
uration 15 days versus 9 days), as well as a higher
equirement for blood and platelet transfusion (52%
ersus 33%). However, because of the small number
f patients studied, none of these observed differences
each statistical signiﬁcance (P  .05).
isease Response and Relapse
Sixty-four patients were evaluable for treatment
esponse after transplantation. CR and PR were at-
ained in 53 (83%) and 7 (11%) patients, respectively.
ifty-six evaluable patients had measurable disease be-
ore transplantation, and 45 (80%) achieved CR some-
ime after transplant. Four patients who had persistent
isease after transplant had all succumbed to disease
rogression at a median of 235 days (range: 39-447
ays) after transplantation.
Overall, 33 patients relapsed at the median time of
52 days (range: 33-663 days) after HCT, of whom 18
ad died of disease progression. The cumulative inci-
ence of relapse or disease progression at 2 years was
0% (95% CI 37%-63%). Of the remaining 15 pa-
ients who were alive at the last follow up, 4 had stable
isease, 2 had progressive disease, 9 achieved CR fol-
owing either with a second allogeneic transplant (N 
), withdrawal of immunosuppressant and DLI (N 
), salvage chemotherapy followed by DLI (N 2), or
matinib (N  1). Competing risks analysis did not
eveal any pretransplantation variables to be signiﬁ-
antly associated with the risk of relapse.
onor Lymphocyte Infusion
Overall, 23 (34%) patients received DLI: 19 for
ersistent or progressive disease and 4 for declining or
ow level of donor chimerism. Median time to the ﬁrst
LI from transplant was 129 days (range: 36-468
ays). A median of 8  106 (range: 1  106 to 1.8 
07) CD3 cells/kg was given with the ﬁrst adminis-
ration of DLI. In 11 patients, a second infusion of
LI with a median dose of 3  107 (range: 5.6  106
o 3.5  107) CD3 cells /kg was given at a median of
6 days (range: 3-72 days) following the ﬁrst DLI.
hree patients received a third dose ranging from
.5-4.0  107 CD3 cells/kg.
Seven patients responded to DLI, and these in-
luded 2 patients with CML with relapsed or persis-
ent disease, 1 patient with relapsed Hodgkin’s dis-
ease, 1 patient with MDS, and 3 patients with relapsed
m
w
r
o
t
d
t
p
S
w
6
a
p
i
t
t
G
o
d
(
r
P
s
w
a
p
e
4
t
a
i
c
j
.
P
M
d
p
.
P
s
s
d
p
3
M
m
H
n
H
t
g
w
a
(
d
i
i
i
c
s
o
c
v
f
o
p
p
p
m
c
a
r
d
(
6
s
(
a
g
4
2
L
n
D
N
a
h
b
m
T
H
<
>
T
G
*
L.-P. Koh et al.798ultiple myeloma. Two patients with relapsed AML
ere given chemotherapy to induce second CR before
eceiving DLI. Both patients remained alive and free
f disease at the latest follow-up.
Five patients developed GVHD (4 of whom were
reated for progressive disease and 1 for decreasing
onor chimerism), with acute presentation in 3 pa-
ients (2 grade II and 1 grade III) and chronic limited
resentation in 2 patients.
urvival Analyses
At the time of last follow-up, 31 (46%) patients
ere alive, at a median follow-up of 22 months (range:
-72 months) after HCT. Of these, 25 (81%) achieved
nd remained in CR, 4 had stable disease, and 2 had
rogressed or relapsed. The causes of death are listed
n Table 4. Thirteen (19%) deaths occurred during
he ﬁrst 100 days after transplantation with majority of
he patients (77%) not receiving MTX as part of
VHD prophylaxis: 1 died of refractory AML, 8 died
f aGVHD, 1 died of pulmonary hemorrhage, and 3
ied of pneumonia.
The 5-year probabilities of OS and PFS were 43%
95% CI 31%-55%) and 28% (95% CI 16%-40%),
espectively (Figure 3A). We determined the current
FS [41,44], based on disease status at the latest as-
essment. In this analysis, we assumed that patients
ho relapsed but reentered and remained in remission
fter appropriate “salvage” therapy (eg, second trans-
lant, chemotherapy, or DLI) were disease-free. The
stimated 5-year current PFS was 36% (95% CI 24%-
8%) (Figure 3A).
Univariate and multivariate analysis demonstrated
hat GVHD prophylaxis regimen and grade III-IV
GVHD were the only 2 factors that had signiﬁcant
mpact on both OS and PFS. Patients given the MTX-
ontaining regimen had signiﬁcantly superior OS (ad-
usted hazard ratio [HR] 0.12, 95% CI 0.06-0.27, P 
001) and PFS (adjusted HR 0.19, 95% CI 0.10-0.38,
 .001) compared to those who received only
MF/CSP (Figure 3B and C; Table 2). Patients who
eveloped grade III-IV aGVHD had signiﬁcantly
oorer OS (adjusted HR 0.28, 95% CI 0.14-0.57, P 
001) and PFS (adjusted HR 0.43, 95% CI 0.23-0.83,
able 4. Causes of Death in 67 Patients Receiving Nonmyeloablative
ematopoietic Cell Transplant
Time GVHD Infection
Relapse/
PD Others*
Death,
N (%)
NRM,
N (%)
100 Days 8 3 1 1 13 (19) 12 (17)
100 Days 6 0 16 1 23 (34) 7 (11)
otal 14 3 17 2 36 (53) 19 (28)
VHD indicates graft-versus-host diesease; NRM, nonrelapse
mortality; PD, progressive disease.
Others include pulmonary hemorrhage (N 1) and suicide (N 1). .001) compared to those who did not. tTable 5 summarizes the outcome of all patients
tratiﬁed by disease categories (AML/myelodysplastic
yndromes [MDS] versus others), disease risk (stan-
ard versus high risk), and postgrafting immunosup-
ression (MTX versus no MTX). As shown in Figure
D and E, patients with diagnosis other than AML/
DS receiving extended MTX-containing postim-
unosuppression had a more favorable OS (adjusted
R 0.33, 95% CI 0.12-0.97, P  .04), but there was
o statistical difference in their current PFS (adjusted
R 0.66, 95% CI 0.27-1.60, P  .35) when compared
o patients with AML/MDS receiving similar post-
rafting immunosuppression. The difference in OS
as attributed to higher incidence of NRM (GVHD
nd infection) seen among the AML/MDS group
22% versus 0%; P  .02). The table also clearly
emonstrates that patients given non-MTX contain-
ng regimens had a dismal outcome with none surviv-
ng in disease-free status at 3 years. This high mortal-
ty may be attributed to both transplant-related
omplications and relapsed disease. Despite demon-
trating a trend toward a higher cumulative incidence
f relapse (50% versus 33%; P  .174), patients re-
eiving MTX had a much superior disease-free sur-
ival (DFS) (14 of 23 patients in CR during the last
ollow-up). This suggests the possible protective effect
f MTX against lethal GVHD and its associated com-
lications, resulting in much lower NRM seen among
atients receiving MTX (Figure 2 and Table 2).
Subgroup analysis was performed on 21 of the 67
atients with “standard risk” diseases (hematologic
alignancies in ﬁrst remission, CML in the ﬁrst
hronic phase, MDS-refractory anemia subtype, and
plastic anemia) and were given the MTX-containing
egimen as postgrafting immunosuppression. The me-
ian age of this subgroup of patients was 43 years
range: 25-62 years) with 6 (29%) patients exceeding
0 years of age. The 3-year OS and PFS for this
ubgroup were 85% (95% CI, 70-100%) and 65%
95% CI, 44-86%) (Figure 3F). This compares favor-
bly with 25 “high-risk” patients given similar post-
rafting immunosuppression, who demonstrated a
1% (95% CI, 19%-63%) 3 year OS (P  .02), and a
3% (95% CI, 15%-31%) 3 year PFS (P  .03).
arger studies with more standard risk patients are
eeded to conﬁrm these encouraging results.
ISCUSSION
Considerable clinical evidence has established that
M conditioning, which relies on optimizing pre-
nd posttransplant immunosuppression to overcome
ost-versus-graft rejection facilitates prompt and sta-
le engraftment, whereas enabling eradication of tu-
ors via its powerful immune-mediated graft-versus-umor effect. More importantly, the procedure was
Figure 3. A, OS, current PFS (CPFS), and PFS of 67 patients undergoing nonmyeloablative allogeneic transplantation. B, OS, and C, PFS of 67 patients undergoing nonmyeloablative allogeneic
transplantation stratiﬁed by postgrafting immunosuppression. D, Overall survival. E, current PFS of 67 patients stratiﬁed by disease categories and post-grafting immunosuppression. F, OS and PFS
of a subgroup of 21 patients with “standard-risk” disease given MTX/MMF/CSP as postgrafting immunousppression.
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L.-P. Koh et al.800emarkably well tolerated, thereby extending the age
ange of potential recipients suitable for transplanta-
ion and included those less medically ﬁt [3,4,36].
espite the considerably lower regimen-related tox-
cities and early mortality compared to conventional
ransplantation, NM HCT is frequently associated
ith severe complications such as aGVHD and
GVHD, resulting in signiﬁcant transplant-related
orbidity and mortality. Even though GVH-reac-
ions ensuing after NM HCT are, in theory, needed
or achieving stable engraftment and for eradication of
nderlying malignant diseases, the prevention of se-
ere aGVHD and its documented associated morbid-
ty and mortality have remained important objectives
14,48,49].
Here, we report our results in a cohort of 67
atients with various hematologic diseases treated
ith 2 similar GVHD prophylaxis regimens. The
resent study conﬁrms results from Seattle that this
M regimen was well tolerated and resulted in a high
ate of engraftment in patients who are otherwise
xcluded from conventional HCT because of age or
omorbidities. The hematologic toxicities of this NM
egimen were moderate with ANCs in approximately
5% of patients not declining below 500/	L and more
han half of the patients not requiring any blood or
latelet transfusion.
In this study, however, an unexpectedly high cu-
ulative incidence of NRM (62% at 1 year) and grade
II-IV aGVHD (52%) were observed among the ﬁrst
ohort of patients receiving CSP/MMF as postgraft-
ng immunosuppression. The 1-year probabilities of
S and PFS on this regimen were 43% and 5%,
espectively. Main causes of NRM were GVHD
85%) and infection (15%). The NRM and severe
able 5. Summary of Outcome of Patients Stratiﬁed by Disease Catego
GVHD Prophylaxis Regimen Total
Alive (Diseas
Last Follow
CR PR/
iagnosis
AML/MDS
No MTX 8 0 0
With MTX 23 11 0
Diagnosis other than AML/MDS
No MTX 13 0 1
With MTX 23 14 3
isease risk
Standard risk
No MTX 13 0 1
With MTX 21 17 1
High risk
No MTX 8 0 0
With MTX 25 8 2
R indicates complete remission; PR, partial remission; SD, stable d
myelodysplastic syndrome; MTX, methotrexate; GVHD, graft-VHD reported here are in excess of that previously teported. In an analysis of the ﬁrst 451 patients from
he Fred Hutchinson Cancer Research Center con-
ortium using similar conditioning and postgrafting
mmunosuppression, grade III-IV aGVHD occurred
n 14% of patients, and the 2-year probabilities of OS
nd NRM were 51% and 22%, respectively [36]. Sim-
lar to most studies on NM HCT, GVHD, and infec-
ions were the main causes of NRM. This study has
hown a relatively higher incidence of severe aGVHD.
revious studies have suggested that this may be at-
ributable to genetic factors, such as ethnic heteroge-
eity, and diversity of major and minor histocompat-
bility frequencies or cytokine gene polymorphism
50,51].
The use of MTX used in conjunction with CSP
as been regarded as the gold standard for GVHD
rophylaxis [25-27]. We therefore hypothesized that
he addition of MTX onto the CSP/MMF combina-
ion would enhance GVHD protection and reduce
ransplant-related morbidity and mortality. With this
pproach, the reduction of NRM and improvement in
urvival was evident in our patient population. This
eduction of NRM, hypothesized to result from the
ddition of MTX, could have resulted from the un-
quivocally lower incidence of grade III-IV aGVHD
20% versus 52%). Despite demonstrating a trend
owards higher probability of relapse in patients given
TX/CSP/MMF (59% versus 33%; P  .174) com-
ared with those given CSP/MMF, addition of MTX
as associated with lower NRM and more favorable
S and PFS. A number of other studies have reported
imilar negative impact of grade III-IV aGVHD on
FS in patients given HCT after reduced intensity or
M conditioning [8,52]. A recent study among recip-
ents of HLA-matched related and unrelated NM
sk Categories, and Postgrafting Immunosuppression
us at
N) Death (Cause of Death) (N)
PD GVHD Infection Relapse/PD Others
0 2 2 4 0
1 3 1 5 2
0 9 0 3 0
1 0 0 5 0
0 9 0 3 0
0 0 1 1 1
0 2 2 4 0
2 3 0 9 1
PD, progressive disease; AML, acute myelogenous leukemia; MDS,
host disease.ries, Ri
e Stat
Up) (
SD
isease;ransplants from Seattle has demonstrated that grades
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GVHD Prophylaxis in Nonmyeloablative Transplant 801II–IV aGVHD resulted in signiﬁcantly increased
RM without measurable protective effects against
ecurrent malignancies. The protective effects against
isease recurrence and the consequent superior PFS
ere exclusively associated with extensive cGVHD
8]. In our study, the overall cumulative incidence of
GVHD was 34%, with a trend toward higher inci-
ence observed in patients receiving MTX-containing
ostgrafting immunosuppression. This higher risk of
GVHD, however, did not compromise the OS and
FS. In light of these results, the prevention of severe
GVHD appeared to be more desirable than the pre-
ention of cGVHD.
Although the reduced intensity of the condition-
ng regimen has resulted in reduced NRM in patients
ith hematologic malignancies, relapse remains an-
ther critical barrier that limits the eventual success of
he procedure [53]. The overall cumulative incidence
f relapse of 50% in this series appears higher than
ost other series of allogeneic transplant recipients
sing nonmyeloblative or reduced-intensity condi-
ioning, which reported relapse rates ranging between
0% and 46% [1,53-57]. Differences in patient selec-
ion and disease stage/type, may to some extent, ac-
ount for the disparity of our results and other series.
High risk” patients consisted of 50% of the subjects
nrolled in our current series. “High risk” in our
eﬁnition and also by others [57], were patients who
id not fulﬁll one of the following criteria: AML/ALL/
yeloma/lymphoma in the ﬁrst remission, CML in
he ﬁrst chronic phase, MDS-refractory anemia,
plastic anemia. These “high-risk” patients were
eemed to be at higher risk of disease progression or
elapse after NM conditioning. Notably, of the 33
atients with relapse, 22 (66.7%) were in the poor risk
ategory. With our series consisting of a signiﬁcant
roportion of patients with unfavorable pretransplant
isease status (ie, not in ﬁrst remission) or disease
ntities with higher risk of relapse, our relapse rate is
omparable with some of the published series using
on-T cell depletion regimens [54,56,58].
In the current study, subgroup analysis of a cohort
f patients given MTX/CSP/MMF showed that pa-
ients with “standard-risk diseases” had a 3-year OS
nd PFS of 85% and 65%, respectively. This com-
ares favorably to the 41% and 23% OS and PFS,
espectively, in patients with poor-risk diseases (P 
05) (data not shown). The difference is attributed to
igher death rate from relapse among the “high risk”
roup (36% versus 5%; P  .02) (Table 5). Our
ndings, together with the other published results,
ave highlighted several important points: (1) the in-
ensity of the conditioning regimen does affect the
ate of relapse with increased risk of relapse noted
fter NM transplantation, although some of the pub-
ished data may be confounded by including a high
roportion of subjects from “high risk” categories. (2) ihe importance of patient selection and pretransplan-
ation disease status in NM SCT, with signiﬁcantly
onger survival in patients with indolent or chemo-
herapy-sensitive malignancies [59,60]. (3) There is a
ontinuing need to investigate the dose intensity of
onditioning regimen for allogeneic transplant of dis-
ases with a higher risk of relapse.
The ability to promote durable engraftment and
liminate severe aGVHD with MMF/CSP/MTX af-
er ﬂudarabine/low dose TBI conditioning has poten-
ial implications for NM allografting of nonmalignant
isease, in which GVHD is especially counterproduc-
ive. We have recently reported encouraging results in
subgroup of 8 multiply-transfused patients with
plastic anemia and paroxysmal nocturnal hemoglobu-
inemia, who received NM allografting using this ap-
roach [61]. Our observations suggested that this ap-
roach allowed prompt and stable engraftment in all
atients. Furthermore, addition of MTX into the post-
rafting immunosuppression effectively avoids fatal
GVHD and resulted in 100%DFS in all 6 patients at a
edian follow-up of 24 months.
Although the combination of CSP and MTX has
een the gold standard for GVHD prophylaxis in
yeloablative transplant for decades [25-27], toxicities
rom MTX, even at low doses, may result in signiﬁ-
ant morbidity and mortality. As an antiproliferative
gent, MTX inhibits GVHD primarily via killing of
ntigen-activated T cells. It also causes tissue damage
nd can activate the initial phase of the GVHD re-
ponse [62,63]. The use of MTX in the GVHD pro-
hylaxis has been associated with oral mucositis, delay
n the time to neutrophil engraftment [25,35], and
ulmonary toxicity [64], which may adversely affect
ransplantation outcome. Two previous comparative
tudies on patients receiving myeloablative HCT have
emonstrated that, when a non-MTX-containing
VHD prophylaxis regimen was used, a faster rate of
ematopoietic engraftment, a decrease in incidence
nd severity of mucositis, and mucositis-related mor-
idities such as total parenteral nutrition (TPN) use,
arcotic use, and hospitalization duration were ob-
erved. Importantly, there was no compromise in
VHD control and survival was similar [65,66]. In the
urrent analysis, the use of an MTX-containing regi-
en was associated with a trend toward higher inci-
ence of mucositis and more severe hematologic tox-
cities. These differences did not reach statistical
ifference, and this was probably because of the small
ample size in our study.
Despite the impressive decrease in grade III-IV
GVHD among MTX-treated patients, the incidence
f cGVHD was not statistically different between the
postgrafting immunosuppression arms. There was,
owever, a trend toward higher incidence of cGVHD
n patients receiving MTX-containing postgrafting
mmunosuppression. This can be explained in part by
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L.-P. Koh et al.802he observation that those patients given a non-MTX-
ontaining regimen who would have been at highest
isk of developing cGVHD died earlier of complica-
ions from aGVHD, whereas comparable MTX-con-
aining regimen-treated patients survived long enough
o be at risk for cGVHD. Previous studies have shown
hat MTX-containing GVHD prophylaxis regimens
ere associated with a lower incidence of cGVHD
fter peripheral blood stem cell (PBSC) or marrow
ransplant using myeloablative transplant condition-
ng [67,68], although this relationship was not con-
rmed by others [69]. It remains unclear whether the
se of MTX has any impact on the risk of cGVHD in
atients receiving NM transplant, in which the use of
BSC has been recognized to be a signiﬁcant com-
ounding factor for cGVHD [70].
In previous studies from Seattle, the lack of stable
ixed chimerism in most patients together with de-
elopment of GVHD in some patients after discon-
inuation of CSP on day 35 led to the extension of
SP administration to day 56 for GVHD control
3,71]. A recent retrospective analysis showed that
onger CSP duration decreased the risk of grade
II-IV aGVHD and increased likelihood of discon-
inuing all systemic immunosuppression when com-
ared to shorter CSP regimens [71]. In the current
tudy, patients given MTX also received an extended
uration of MMF and CSP. It is possible that the
ifference in the risk of aGVHD resulted from the
rotective effect of extended MMF/CSP rather than
he effect of MTX alone. However, the impact of
xtended CSP/MMF on the severity or severity of
GVHD could not be adequately addressed in the
urrent study because many patients receiving the
on-MTX-containing postgrafting immunosuppres-
ants were still on CSP/MMF prophylaxis at the time
cute GVHD developed. Also, our evaluation is fur-
her hindered by the fact that many patients remained
n CSP/MMF longer than speciﬁed by protocols be-
ause of occurrence of aGVHD. In our study, we did
ot ﬁnd signiﬁcant differences in the time to onset of
VHD nor in the cumulative incidence of grades
I-IV aGVHD between the 2 immunosuppressive reg-
mens. This suggested that the addition of MTX did
ot affect the time of onset or overall incidence of
rade II-IV aGVHD but rather prevented progression
f this complication to grade III-IV aGVHD.
The primary limitation of this study is that this
nding was based on a relatively small number of
atients. In addition, the effect of the 2 immunosup-
ressive regimens was not studied within the context
f randomized controlled trial. Hence, it is possible
hat outcome was inﬂuenced by latent covariates that,
lthough unknown, were both unevenly distributed.
lso, it should be noted that other differences in
ractice over time beside alteration of immunosup-
ressive regimen could have inﬂuenced the outcomen the present study. Nevertheless, the encouraging
esults seen in this small cohort of patients provides
ationale to assess the feasibility of this approach in
arger number of patients.
In conclusion, we have shown that the addition of
TX onto the current postgrafting immunosuppres-
ion regimen with extended CSP/MMF prophylaxis
uration offers the possibility of further optimization
f GVHD control in patients receiving ﬂudarabine/
ow-dose TBI NM conditioning. This immunosup-
ressive regimen decreased the risk of grade III-IV
GVHD, resulting in lower NRM and improved sur-
ival. Protection against severe aGVHD did not affect
isks of cGVHD or relapse. Future prospective studies
re needed to determine whether substituting alterna-
ive calcineurin inhibitors, such as tacrolimus, for CSP
72], might be more effective in preventing severe or
herapy-refractory GVHD without compromising en-
raftment and control of the underlying malignancies.
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